Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

v3.2.0.727
Subsequent Events - Additional Information (Detail)
 12 Months Ended
Jan. 30, 2014
USD ($)
shares
Jan. 23, 2014
USD ($)
Subsidiary
shares
Dec. 31, 2013
USD ($)
$ / shares
Dec. 31, 2012
USD ($)
$ / shares
Jan. 23, 2014
£ / shares
Subsequent Event [Line Items]          
Estimated fair value of common stock | $ / shares     $ 0.01 $ 0.01  
Acquisition-related costs     $ 2,200,000 $ 0  
Serum Institute Of India Limited [Member]          
Subsequent Event [Line Items]          
Issuance of common stock       1,472,155  
Symbio Tec Gmbh [Member]          
Subsequent Event [Line Items]          
Issuance of common stock       $ 9,258,326  
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Issuance of common stock, Shares | shares   132,545,504      
Reverse merger consideration transferred   $ 3,750,000      
Equity interest issued   9.20%      
Estimated fair value of common stock | £ / shares         £ 0.06
Transaction costs   $ 3,000,000      
Purchase price allocation description   The Company expects to finalize the valuation and complete the purchase price allocation as soon as practicable but no later than one year from the acquisition date.      
Number of subsidiaries sold | Subsidiary   2      
Subsequent Event [Member] | Baxter Healthcare [Member]          
Subsequent Event [Line Items]          
Issuance of common stock $ 10,000,000        
Issuance of common stock, Shares | shares 10,695,187        
Percentage of increase in share ownership 10.00%        
Subsequent Event [Member] | Oxbridge [Member]          
Subsequent Event [Line Items]          
Share outstanding common stock cancelled | shares   10,000,000      
Cash paid for Hive Out Agreement   $ 430,000      
First Quarter Two Thousand Fourteen [Member]          
Subsequent Event [Line Items]          
Loss on disposal of subsidiaries     $ 1,069,675